About: Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 February 1996

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в лютому 1996 (uk) article scientifique publié en 1996 (fr) im Februar 1996 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en febreru de 1996 (ast) artikull shkencor i botuar më 01 shkurt 1996 (sq) scientific article published on 01 February 1996 (en)
publication date	wds:Q71809729-E500C7EF-3939-4C1F-AEB6-21AB914581EC
publication date	1996-02-01 00:00:00Z (xsd:dateTime)
cites work	wds:Q71809729-1498FF79-9334-424C-A4B9-94C82D1D69CC wds:Q71809729-166CC2EE-1034-430F-BA21-5437DA437C59 wds:Q71809729-1EDDBF2C-44A7-4A83-B847-3844609C55EF wds:Q71809729-36393FEF-B07A-47EE-9C11-B100FAAC1232 wds:Q71809729-3B9865E7-19C7-42D7-83B6-EFB114AECAC2 wds:Q71809729-58D85DC1-5B9E-49D5-A7F2-E32A415B7E16 wds:Q71809729-61F1F5A6-B32E-4E11-85C9-61CD71233C31 wds:Q71809729-8575CF99-8858-438F-99AA-FE1AAD3E135E wds:Q71809729-A1C711A6-FF8A-4C86-9F11-BF255C80EBF6 wds:Q71809729-A95197F5-88B0-421C-A5F2-93778AFCFCA7 wds:Q71809729-B1C617A8-B20D-4FB9-BAF9-E06EA67D30CB wds:Q71809729-BA5B8860-ED95-4697-8FFA-F7B08C737A4D wds:Q71809729-C27C67A6-EAC9-4727-8056-16D774227A0F wds:Q71809729-C84D8C42-AD5C-4326-9F87-319713D5D15F wds:Q71809729-CAAD5956-2190-4579-BB47-E06CCEDD6BFF wds:Q71809729-DEBA03EE-5C24-4996-8638-7906038D5759 wds:Q71809729-E30AD93B-07D8-433B-93D6-FC0796A15E95 wds:Q71809729-E8EF39D7-AF9E-45A7-9D5D-2ADDE224DB43 wds:Q71809729-F7A2505E-8796-4035-8C08-B70C2B7CDBDD wds:Q71809729-FF1ED0CB-97E5-4238-A91E-C72090C61293
cites work	A phase II trial of VP 16-213 in adults with refractory acute myeloid leukemia. An Eastern Cooperative Oncology Group study Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Polystyrene-poly (ethylene glycol) (PS-PEG2000) particles as model systems for site specific drug delivery. 2. The effect of PEG surface density on the in vitro cell interaction and in vivo biodistribution Phase I study of taxol administered as a short i.v. infusion daily for 5 days. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease Biodegradable long-circulating polymeric nanospheres Lipid emulsions as drug delivery systems Long-circulating (sterically stabilized) liposomes for targeted drug delivery Successful re-treatment with taxol after major hypersensitivity reactions. The current status of camptothecin analogues as antitumor agents The clinical pharmacology of etoposide Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy Design, synthesis and biological activity of protaxols Improved oral absorption of a poorly water-soluble drug, HO-221, by wet-bead milling producing particles in submicron region A method for the preparation of submicron particles of sparingly water-soluble drugs by precipitation in oil-in-water emulsions. II: Influence of the emulsifier, the solvent, and the drug substance Interaction of serum components with poly(methylmethacrylate) nanoparticles and the resulting body distribution after intravenous injection in rats Hypersensitivity reactions induced by etoposide Effects of hydrotropic agents on the solubility, precipitation, and protein binding of etoposide Midwest Cooperative Group evaluation of piposulfan (A-20968) in cancer Clinical experience with 1,4-dihydracryloylpiperazine, dimethanesulfonate (NSC-47774)
author name string	wds:Q71809729-013C4D9A-F736-4F5D-A677-B55FAD36B19C wds:Q71809729-1096733A-36D5-4EFF-A160-570BB172ABFF wds:Q71809729-2F2C2267-707C-4BBD-BEC3-D89CECB64066 wds:Q71809729-37042624-C457-4D96-A76F-8CF0588FDDAD wds:Q71809729-51BD36B7-98A4-45A5-9CB1-508F0CE18C71 wds:Q71809729-71B9A8FB-A816-4B8D-B9AB-33C57FA8610A wds:Q71809729-74BB75CF-00AC-4FF5-9778-ABD7DA309FF9 wds:Q71809729-7EAF6FA8-1C37-4BC0-B01C-8B3A15AA7B91 wds:Q71809729-8A4FC919-EA40-45E9-BC05-406E92F404E9 wds:Q71809729-A00BCC2C-450E-4B51-9B6C-07DCF42F0F2E wds:Q71809729-C81356F7-F2EC-46E1-9FC1-26D7525D2812 wds:Q71809729-E3BB9C0D-EB64-4639-9E7F-596337EFA434 wds:Q71809729-F4232FA7-309B-4940-AF31-12EDB1953B71 wds:Q71809729-F569F71E-B9EB-41F9-A115-8A2DCA4149BA
author name string	J Bruno L Wei J Jones J M Shaw T Corbett E Cooper S Pugh L Polin G G Liversidge N Peltier S Hajj E Merisko-Liversidge J Rake P Sarpotdar
rdfs:label	Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs (en) Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs (nl) Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs (sq)
skos:prefLabel	Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs (en) Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs (nl) Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs (sq)
name	Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs (en) Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs (nl) Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs (sq)
title	wds:Q71809729-21140138-BDBF-4BD7-B1C7-DFDE86F4B888
title	Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs (en)
page(s)	wds:Q71809729-DE505FAA-7D05-4E99-B3C4-A02F8CCCACE1
page(s)	272-278
instance of	wds:Q71809729-27202DD7-3475-453E-A76C-198ECDDBA57E
instance of	scholarly article
PubMed ID	wds:Q71809729-18A7E6E0-6E49-438F-850A-B47C80356A88
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8932448
PubMed ID	8932448
published in	wds:Q71809729-CC20F545-4865-4275-ADE6-DF1D3D5BC597
published in	Pharmaceutical Research
issue	wds:Q71809729-2BBA039A-7995-43EE-B641-C2E751253A51
volume	wds:Q71809729-8828E2B0-76AD-42E1-98D3-DABB86A6B6D1

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software